Healthcare Industry News: TomoTherapy
News Release - March 24, 2009
TomoTherapy Announces First Middle East Installation of Hi-Art Cancer Treatment SystemSaudi Arabia’s renowned King Faisal Specialist Hospital & Research Centre will become region’s first to treat cancer patients with next-generation radiation therapy solution
MADISON, Wis.--(HSMN NewsFeed)--TomoTherapy Incorporated (NASDAQ: TOMO ) announced today that Saudi Arabia’s leading cancer center, King Faisal Specialist Hospital & Research Centre (KFSH&RC) in Riyadh, will become the region’s first to treat patients with the Hi·Art® treatment system, a next-generation radiation therapy solution designed to improve the precision of cancer care. KFSH&RC commemorated the historic Hi·Art treatment system installation in a ribbon-cutting ceremony during a scientific meeting held at the hospital March 9-12, 2009.
The meeting, entitled “Innovative Approaches in Radiotherapy: Beyond Tomorrow”, attracted radiation oncology professionals from throughout the country and featured an impressive roster of speakers, including TomoTherapy co-founder and Chairman of the Board Thomas “Rock” Mackie, Ph.D.
“It was an honor for me to attend both the scientific meeting and Hi·Art system opening ceremony hosted by King Faisal Specialist Hospital & Research Centre,” said Dr. Mackie. “TomoTherapy is extremely pleased to partner with this world-renowned centre as it implements the only solution designed to deliver on the promises of image-guided, intensity-modulated radiation therapy (IG-IMRT).”
TomoTherapy’s Hi·Art treatment system is unique among radiation therapy devices in its computed tomography (CT) scanner-based design. The system allows clinicians to efficiently acquire a true CT image of the patient immediately before daily treatment to help ensure accuracy. Then, using the same equipment as used in imaging, the treatment team can deliver highly-precise radiation in a continuous, 360-degree (helical) pattern.
“We look forward to employing TomoTherapy® treatment technology to benefit our patients in terms of minimization of dose to normal tissue and improvement of side-effect related outcomes,” said Dr. Mohammad Al-Shabanah, Section Head, Radiation Oncology, KFSH&RC. “One area of interest for us is the use of total marrow irradiation to support our large bone marrow transplant program.”
Added Dr. Belal Moftah, Chairman, Department of Biomedical Physics, KFSH&RC: “We are very excited at King Faisal Specialist Hospital & Research Centre to open our TomoTherapy unit, which is the first in the Middle East. We plan on maximizing the advantages of integrated CT imaging and highly-modulated beam delivery that TomoTherapy provides. Additionally, we are extremely satisfied with the speed of installation and professionalism of both TomoTherapy and its distribution partner in Saudi Arabia, Attieh Medico.”
About King Faisal Specialist Hospital & Research Center
King Faisal Specialist Hospital & Research Center (KFSH&RC) is an 894-bed multi-facility, multi-entity tertiary care hospital and one of the leading healthcare institutions in the Kingdom of Saudi Arabia. Its mission is to provide medical services of a highly-specialized nature and to promote medical research and education programs, including postgraduate education training, as well as to contribute to the prevention of disease.
About Attieh Medico
Attieh Medico, Ltd., is a leading medical technology company in the Kingdom of Saudi Arabia, representing various internationally-renowned manufacturers of a wide range of high-tech, state-of-the-art medical equipment. Attieh Medico assumed responsibility for supplying and maintaining the innovative TomoTherapy® Hi·Art® cancer treatment system in June 2008. For more information on Attieh Medico, please visit AttiehMedico.com.
About TomoTherapy Incorporated
TomoTherapy Incorporated has developed, markets and sells the TomoTherapy® Hi·Art® treatment system, an advanced radiation therapy system for the treatment of a wide variety of cancers. The Hi·Art treatment system combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The company’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.
©2009 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Tomo, the TomoTherapy logo and Hi·Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.